Is Janux Therapeutics, Inc. (JANX) a Buy, Sell, or Hold?
NASDAQ : JANX
Janux Therapeutics, Inc.
$16.26 USD
$0.42 (2.65%)
- Volume
- 775.16K
- Average Volume
- 1.13M
- Market Capitalization
- $991.61M
- P/E Ratio
- -8.84
- Dividend Yield
- 0.00%
- Price Target
- $22.00
- Year High
- $35.34
- Year Low
- $12.12
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $17.01
| Source | Headline |
|---|---|
|
Wall Street Analysts Predict a 155.82% Upside in Janux Therapeutics (JANX): Here's What You Should Know
The mean of analysts' price targets for Janux Therapeutics (JANX) points to a 155.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. zacks.com - 2026-05-28 10:56:12 |
|
Here's Why You Should Add JANX Stock to Your Portfolio Now
Janux Therapeutics advances multiple oncology and immune therapy programs with key clinical updates, new studies and expanded partnerships with BMY and MRK. zacks.com - 2026-05-26 12:31:08 |
|
Janux Therapeutics, Inc. (JANX) Reports Q1 Loss, Lags Revenue Estimates
Janux Therapeutics, Inc. (JANX) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.5. This compares to a loss of $0.38 per share a year ago. zacks.com - 2026-05-07 20:11:30 |
|
Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial results for the quarter ended March 31, 2026, and provided a business update. "Our commitment to advancing a prostate cancer franchise is demonstrated by our continued progress with JANX007, clinical initiation of JANX014, and advancement of JANX013 toward the clinic,” said David Campbell, Ph.D., Pr. businesswire.com - 2026-05-07 16:01:00 |
|
How Much Upside is Left in Janux Therapeutics (JANX)? Wall Street Analysts Think 180.44%
The consensus price target hints at an 180.4% upside potential for Janux Therapeutics (JANX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. zacks.com - 2026-05-07 10:55:35 |
|
Janux Therapeutics: Strong Buy As Pipeline Advances, Stock Trades Below Cash Value
Janux Therapeutics, Inc. is upgraded to Strong Buy, trading below cash value with a robust cash runway and validated technology platforms. Discontinuation of JANX008 demonstrates financial discipline, reallocating resources to higher-potential assets and further validating the TRACTr platform. Strategic partnerships with Merck and BMY could yield up to $1.8 billion in milestones plus royalties, supporting long-term value creation. seekingalpha.com - 2026-05-04 19:33:55 |
|
Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (“Janux”), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced that it will discontinue further clinical development of JANX008, its EGFR-targeted Tumor Activated T Cell Engager (TRACTr) program. Following completion of the Phase 1a portion of the study, which included dose escalation and expansion cohorts across multiple solid tumor indications, and an internal revie. businesswire.com - 2026-04-27 16:01:00 |
